Cocrystal Pharma Inc COCP 深 沪
等待开盘 05-12 09:30:00 美东时间
1.30
-0.150
-10.34%
华盛通- 最 高1.45
- 今 开1.40
- 成交量 18.64万股
- 最 低 1.29
- 昨 收 1.45
- 总市值 12.67万
- 52周最高 2.67
- 市盈率 静 --
- 换手率 191.23%
- 52周最低 0.8588
- 委 比 -8.47%
- 总股本 9.75万
- 历史最高 5.50
- 量 比 1.20
- 振 幅 11.03%
- 历史最低 0.221
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Cocrystal Pharma Shares Are Cooling Off Monday?
COCP stock is trading lower Monday morning. Learn why Cocrystal Pharma is seeing a pullback after receiving FDA Fast Track designation for CDI-988.
04-06 21:28
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Quarry Inc. and Cocrystal Pharma Inc. shares increase.
04-03 01:30
Nasdaq Down 1%; US Initial Jobless Claims Fall
US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer discretionary stocks fell. US jobless claims declined.
04-02 22:44
Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988
Cocrystal Pharma Inc. (NASDAQ:COCP) shares are trading higher Thursday after it received Fast Track designation from the FDA for its CDI-988.
04-02 22:03
Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
Cocrystal Pharma's CDI-988, a broad-spectrum protease inhibitor for norovirus prevention and treatment, will be presented at the 2025 Military Health System Research Symposium. The drug targets viral replication machinery and has completed Phase 1 trials.
2025-06-05 12:00
Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
Cocrystal Pharma's compound CC-42344 shows strong antiviral activity against the 2024 Texas H5N1 avian influenza virus, with potency 1,000-fold higher than Tamiflu. The drug targets the PB2 protein of the virus and is in development for treating pandemic and seasonal influenza. The study highlights its potential as a novel treatment amid concerns of H5N1 spread and limited human immunity.
2025-05-29 12:00
Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
Cocrystal Pharma, Inc. will participate in a fireside chat at Noble Capital Markets’ virtual conference on June 5, 2025. investors can register for the event and request one-on-one meetings. a webcast of the presentation will be available on the company’s website and Channelchek for 90 days.
2025-05-28 12:00
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 Into Phase 1 Multiple-Ascending Dose Cohorts; Topline Study Results Are Expected In Late 2024 Or Early 2025
Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces dosing of the first subjects in the multiple-ascending dose (MAD) portion of the Phase 1 study with CDI-988, its potent, broad-spectrum, oral
2024-09-26 20:03
Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Evercore ISI Group raised the price target for Walmart Inc. (NYSE:WMT) from $78 to $80. Evercore ISI Group ana...
2024-08-22 21:22
HC Wainwright & Co. Maintains Buy on Cocrystal Pharma, Lowers Price Target to $7
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cocrystal Pharma (NASDAQ:COCP) with a Buy and lowers the price target from $10 to $7.
2024-08-22 20:45
